![Quiver Logo](/static/img/logo-icon.png)
![ABVX logo](https://quiver-logos.s3.us-east-2.amazonaws.com/abvx.png)
Abivax SA American Depositary Shares
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ABVX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of ABVX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ABVX's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to ABVX
Recent picks made for ABVX stock on CNBC
ETFs with the largest estimated holdings in ABVX
Flights by private jets registered to ABVX
![Quiver Logo](/static/img/logo-icon.png)